Lipocine Inc. Starts Phase 3 Trial of LPCN‑1154 for Postpartum Depression

What Happened
Lipocine Inc. (LPCN) announced on September 14, 2026 (via a Form 8‑K, Item 8.01) that it has initiated the BLOOM Phase 3 study of LPCN‑1154 to treat postpartum depression. The company furnished a press release announcing the trial start as Exhibit 99.1 to the 8‑K.

Key Details

• Event filed on Form 8‑K dated September 14, 2026 (Accession No. 0001493152-26-042466).
• Study name: BLOOM Phase 3 Study of LPCN‑1154 (indication: postpartum depression).
• Press release announcing the initiation is included as Exhibit 99.1 and incorporated by reference.
• Reported under Item 8.01 (Other Events); exhibits listed under Item 9.01.

Why It Matters
Advancing LPCN‑1154 into a Phase 3 (pivotal) trial is a major clinical milestone for Lipocine as it moves the candidate closer to potential regulatory review if results are positive. For investors, this is a material development to watch—future trial progress, timelines, and clinical readouts could have significant implications for the company’s value and development strategy. Monitor company updates and published trial data for further details.